Prelude director granted 38,000 stock options

Prelude Therapeutics Inc director David P. Bonita received a grant of stock options covering 38,000 shares of Common Stock.

Rhea-AI Filing Summary

Prelude Therapeutics Inc director David P. Bonita received a grant of stock options covering 38,000 shares of Common Stock. The options have an exercise price of $3.94 per share and expire on June 8, 2036. The award will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, subject to continued service. Under an agreement, any securities or economic benefit from these options are required to be transferred to OrbiMed-related entities.

Insider Trade Summary

Grant/Award: 38,000 shares

Grant/Award 1 txn

Insider Bonita David P

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	38,000	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 38,000 contracts (Direct)

Footnotes (2)

1. F1. The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
2. F2. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.

Key Figures

Option grant size: 38,000 options Exercise price: $3.94 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option grant size 38,000 options Director stock option covering Common Stock

Exercise price $3.94 per share Conversion or exercise price of options

Expiration date June 8, 2036 Option expiration for director grant

Shares underlying options 38,000 shares Underlying Common Stock issuable on exercise

Post-transaction derivative holdings 38,000 options Total derivative securities following transaction

Key Terms

Director Stock Option (Right to Buy), grant/award acquisition, exercise price, annual stockholder meeting, +1 more

5 terms

Director Stock Option (Right to Buy) financial

"security_title: Director Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 3.9400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual stockholder meeting financial

"will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

economic benefit financial

"or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Prelude Therapeutics (PRLD) report for David P. Bonita?

Prelude Therapeutics reported that director David P. Bonita received a grant of stock options for 38,000 shares of Common Stock. These are compensation-related awards, not open-market purchases or sales, and are structured as options to buy shares at a fixed exercise price.

What are the key terms of the 38,000 Prelude Therapeutics (PRLD) stock options?

The reported options cover 38,000 shares of Common Stock at an exercise price of $3.94 per share. They expire on June 8, 2036, giving a long-dated right to purchase shares at that price if the award vests and is exercised.

When do David P. Bonita’s Prelude Therapeutics (PRLD) options vest?

The option award will fully vest on the earlier of Prelude’s next annual stockholder meeting or the one-year anniversary of the grant date. Vesting is conditioned on David P. Bonita continuing to provide service to the company through the applicable vesting date.

Who ultimately benefits from the Prelude Therapeutics (PRLD) option grant reported for David P. Bonita?

Under an agreement, any securities or economic benefits from these stock options must be transferred to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC. These entities will ensure that the securities or benefits are provided to OrbiMed Private Investments VI, LP.

Is the Prelude Therapeutics (PRLD) Form 4 transaction an open-market buy or sell?

The Form 4 reports a grant or award acquisition of stock options, coded as an “A” transaction. It is a compensation-related derivative award, not an open-market purchase or sale of existing Prelude Therapeutics Common Stock in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonita David P

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DELAWARE 19805

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$3.94	06/09/2026		A		38,000		(1)	06/08/2036	Common Stock	38,000	$0.00	38,000	D(2)

Explanation of Responses:

1. The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

2. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.

Remarks:

	/s/ Krishna Vaddi, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)